NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders
Summary
AMSTERDAM, December 17, 2021--(BUSINESS WIRE)--NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today announces the close of a USD 80 million Series C financing round. Dirk Kersten, General Partner at Forbion Growth, added: "We believe NST’s management team has done an exceptional job in enrolling one of the largest ongoing phase 2B study in NASH, despite challenging times during the Covid-19 pandemic. Forbion Growth is looking forward to teaming up with the syndicate of high-quality investors from the US and Europe and supporting the Company in preparing for the phase 3 development of Icosabutate, as well as progressing the other SEFA programs in the pipeline in the clinic." The structural modifications result in high hepatic concentrations of non-esterified icosabutate that in turn optimise targeting of fatty acid receptors of key relevance to NASH, including FFAR4. NorthSea Therapeutics B.V.(NST) is a Dutch biotech company focused on developing structurally engineered fatty acids (‘SEFAs’) for the treatment of NASH and other metabolic disorders.